Premium
A 12‐week double‐blind multi‐centre study of paroxetine and imipramine in hospitalized depressed patients
Author(s) -
Arminen S.L.,
Ikonen U.,
Pulkkinen P.,
Lein E.,
Mahlanen A.,
Koponen H.,
Kourula K.,
Ryyppö J.,
Korpela V.,
Lehtonen M. L.,
Vartiainen H.,
Lehtinen V.,
Tamminen T.,
Manniche P. M.
Publication year - 1994
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1994.tb01533.x
Subject(s) - paroxetine , rating scale , imipramine , antidepressant , depression (economics) , psychology , hamilton rating scale for depression , psychiatry , statistical significance , significant difference , medicine , side effect (computer science) , major depressive disorder , alternative medicine , anxiety , developmental psychology , cognition , macroeconomics , pathology , computer science , economics , programming language
Fifty‐seven inpatients with major depression (DSM‐III‐R) entered a 12‐week study comparing paroxetine and imipramine. Trends (not reaching statistical significance) in favour of paroxetine were seen on the Hamilton Depression Rating Scale (HDRS) and the Montgomery‐Åsberg Depression Rating Scale (MADRS). The UKU Side Effect Rating Scale showed a significant difference in favour of paroxetine on reduced salivation. Global evaluation of side effect symptoms showed that significantly more paroxetine patients had no side effects, both in the investigators’ and the patients’ opinion. These results are in line with previous findings of paroxetine being an effective and well tolerated antidepressant.